Recursion

Recursion is a techbio company that uses artificial intelligence to accelerate drug discovery. The company's platform combines hardware, software, and data to create a more efficient and effective drug discovery process. Recursion has a broad pipeline of drug candidates in development, and it has partnered with several leading pharmaceutical companies. The company is headquartered in Salt Lake City, Utah.

Insitro is a drug discovery and development company that uses machine learning and data to identify and develop new medicines. The company's platform integrates in vitro cellular data produced in its labs with human clinical data to help redefine disease. Insitro's pipeline includes wholly-owned and partnered therapeutic programs in metabolism, oncology, and neuroscience.

Atomwise is an AI-powered drug discovery company that uses machine learning to identify new small molecule medicines. The company's platform combines the power of convolutional neural networks with massive chemical libraries to discover new drug candidates. Atomwise has a portfolio of wholly owned and co-developed pipeline assets, and is backed by prominent investors.

Atomwise is an artificial intelligence (AI)-driven drug discovery company that uses machine learning to discover and develop new small molecule medicines. The company's AI engine combines the power of convolutional neural networks with massive chemical libraries to identify new drug candidates. Atomwise has a wholly owned pipeline of drug discovery programs and also partners with other pharmaceutical companies to co-develop drugs. The company's investors include prominent venture capital firms and pharmaceutical companies.

Variational AI is a company that uses generative AI to discover novel drug-like small molecules with optimized properties for defined targets. Their platform, Enki™, is the first commercially accessible foundation model for small molecules. It is designed to make generating novel molecule structures easy, with no data required. Users simply define their target product profile (TPP) and Enki does the rest. Enki is an ensemble of generative algorithms trained on decades worth of experimental data with proven results. The company was founded in September 2019 and is based in Vancouver, BC, Canada.

Valo is a company that uses AI-driven technology to transform the discovery and development of life-changing medicines. They combine machine learning, tissue biology, and patient data to create a suite of powerful capabilities that bring the future of drug discovery and development to bear. Valo's team of software engineers, data scientists, biologists, medicinal chemists, and big-picture thinkers are dedicated to advancing the combined power of technology and patient data.

The Institute for Protein Design is a research institute at the University of Washington that uses computational design to create new proteins that solve modern challenges in medicine, technology, and sustainability. The institute's research focuses on developing new protein therapeutics, vaccines, drug delivery systems, biological devices, self-assembling nanomaterials, and bioactive peptides. The institute also has a strong commitment to responsible AI development and has developed a set of principles to guide its use of AI in research.

BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, techniques. The company's proprietary AI platform is used to identify, re-innovate, and develop potential new therapies. BioXcel Therapeutics has a pipeline of product candidates in various stages of development, including BXCL501 for agitation in dementia, BXCL701 for cocaine use disorder, and BXCL801 for acute suicidal ideation and behavior in patients with major depressive disorder.

Freenome is a healthcare company that uses artificial intelligence and multiomics technology to detect cancer in its earliest stages through a simple blood draw. The company's mission is to make early cancer detection more accessible and affordable, and to improve the chances of successful treatment.

Exscientia is a technology-driven drug design and development company that combines precision design with integrated experimentation to create more effective medicines for patients faster. They operate at the interfaces of human ingenuity, artificial intelligence (AI), automation, and physical engineering, pioneering the use of AI in drug discovery. Exscientia aims to change the underlying economics of drug discovery by rapidly advancing the best scientific ideas into medicines for patients.

JADBio is an automated machine learning (AutoML) platform designed to accelerate biomarker discovery and drug development processes. It offers a no-code solution that automates the discovery of biomarkers and interprets their role based on research needs. JADBio can parse multi-omics data, including genomics, transcriptome, metagenome, proteome, metabolome, phenotype/clinical data, and images, enabling users to efficiently discover valuable insights. The platform is purpose-built for various conditions such as cancer, immune, endocrine, metabolic system, chronic diseases, aging, infectious diseases, and mental health, offering solutions for early biomarker discovery, drug repurposing, lead identification, compound optimization, trial monitoring, and response to treatment. JADBio is trusted by partners in precision health & medicine and is continuously evolving to disrupt drug discovery times and costs at all stages.

Blue River Technology is a company that creates intelligent machinery for agriculture. They use computer vision, machine learning, and robotics to create solutions that help farmers improve yields and minimize their environmental impact. The company is committed to creating a people-first culture where everyone has a common mission: to solve monumental challenges in agriculture.

ESTsoft is a South Korean software company that develops and markets a wide range of software products and services, including operating systems, database management systems, and application software. The company was founded in 1995 and is headquartered in Seoul, South Korea. ESTsoft's mission is to "make the world more convenient and safer through AI." The company's products and services are used by a wide range of customers, including governments, businesses, and individuals. ESTsoft is a publicly traded company and is listed on the Korea Exchange. The company has a strong commitment to research and development and invests heavily in new technologies. ESTsoft has a number of partnerships with other companies, including Microsoft, IBM, and Oracle. The company is also a member of the World Economic Forum.

NVIDIA is a world leader in artificial intelligence computing. The company's products and services are used by businesses and governments around the world to develop and deploy AI applications. NVIDIA's AI platform includes hardware, software, and tools that make it easy to build and train AI models. The company also offers a range of cloud-based AI services that make it easy to deploy and manage AI applications. NVIDIA's AI platform is used in a wide variety of industries, including healthcare, manufacturing, retail, and transportation. The company's AI technology is helping to improve the efficiency and accuracy of a wide range of tasks, from medical diagnosis to product design.

Freenome is a healthcare company that uses artificial intelligence and multiomics technology to detect cancer in its earliest stages through a simple blood draw. The company's mission is to make early cancer detection more accessible and affordable, and to improve the chances of successful treatment.

Google DeepMind is a British artificial intelligence research laboratory owned by Google. The company was founded in 2010 by Demis Hassabis, Shane Legg, and Mustafa Suleyman. DeepMind's mission is to develop safe and beneficial artificial intelligence. The company's research focuses on a variety of topics, including machine learning, reinforcement learning, and computer vision. DeepMind has made significant contributions to the field of artificial intelligence, including the development of AlphaGo, the first computer program to defeat a professional human Go player.

Recursion is a techbio company that uses artificial intelligence to accelerate drug discovery. The company's platform combines hardware, software, and data to create a more efficient and effective drug discovery process. Recursion has a broad pipeline of drug candidates in development, and it has partnered with several leading pharmaceutical companies. The company is headquartered in Salt Lake City, Utah.

Iambic Therapeutics is a cutting-edge AI-driven drug discovery platform that tackles the most challenging design problems in drug discovery, addressing unmet patient need. Its physics-based AI algorithms drive a high-throughput experimental platform, converting new molecular designs to new biological insights each week. Iambic's platform optimizes target product profiles, exploring multiple profiles in parallel to ensure that molecules are designed to solve the right problems in disease biology. It also optimizes drug candidates, deeply exploring chemical space to reveal novel mechanisms of action and deliver diverse high-quality leads.

Insitro is a drug discovery and development company that uses machine learning and data to identify and develop new medicines. The company's platform integrates in vitro cellular data produced in its labs with human clinical data to help redefine disease. Insitro's pipeline includes wholly-owned and partnered therapeutic programs in metabolism, oncology, and neuroscience.

BioXcel Therapeutics, Inc. is a clinical-stage biopharmaceutical company developing transformative medicines in neuroscience and immuno-oncology utilizing artificial intelligence, or AI, techniques. The company's proprietary AI platform is used to identify, re-innovate, and develop potential new therapies. BioXcel Therapeutics has a pipeline of product candidates in various stages of development, including BXCL501 for agitation in dementia, BXCL701 for cocaine use disorder, and BXCL801 for acute suicidal ideation and behavior in patients with major depressive disorder.

Atomwise is an AI-powered drug discovery company that uses machine learning to identify new small molecule medicines. The company's platform combines the power of convolutional neural networks with massive chemical libraries to discover new drug candidates. Atomwise has a portfolio of wholly owned and co-developed pipeline assets, and is backed by prominent investors.

Biofourmis is a healthcare technology company that provides a connected technology platform for care delivery and drug development. The platform enables healthcare systems and pharmaceutical companies to deliver care and conduct clinical trials remotely, and to collect and analyze data to improve patient outcomes. Biofourmis's solutions have been shown to improve clinical, operational, and economic outcomes, such as reducing 30-day readmissions by 70%, detecting deterioration 21 hours sooner, and reducing cost of care by up to 38%.

AiCure provides a patient-centric eClinical trial management platform that enhances drug development through improved medication adherence rates, more powerful analysis and prediction of treatment response using digital biomarkers, and reduced clinical tech burden. AiCure's solutions support traditional, decentralized, or hybrid trials and offer flexibility to meet the needs of various research designs.

IXICO is a precision analytics company specializing in intelligent insights in neuroscience. They offer a range of services for drug development analytics, imaging operations, and post-marketing consultancy. With a focus on technology and innovation, IXICO provides expertise in imaging biomarkers, radiological reads, volumetric MRI, PET & SPECT, and advanced MRI. Their TrialTracker platform and Assessa tool utilize innovation and AI for disease modeling and analysis. IXICO supports biopharmaceutical companies in CNS clinical research with cutting-edge neuroimaging techniques and AI technology.

Valo is a company that uses AI-driven technology to transform the discovery and development of life-changing medicines. They combine machine learning, tissue biology, and patient data to create a suite of powerful capabilities that bring the future of drug discovery and development to bear. Valo's team of software engineers, data scientists, biologists, medicinal chemists, and big-picture thinkers are dedicated to advancing the combined power of technology and patient data.

Atomwise is an artificial intelligence (AI)-driven drug discovery company that uses machine learning to discover and develop new small molecule medicines. The company's AI engine combines the power of convolutional neural networks with massive chemical libraries to identify new drug candidates. Atomwise has a wholly owned pipeline of drug discovery programs and also partners with other pharmaceutical companies to co-develop drugs. The company's investors include prominent venture capital firms and pharmaceutical companies.

Deepcell is a company that develops technology for single-cell analysis. Their REM-I platform combines label-free imaging, deep learning, and gentle sorting to leverage single cell morphology as a high-dimensional quantitative readout. This allows researchers to gain insights into cells' phenotype and function to address important research questions across biology.

Recursion is a techbio company that uses artificial intelligence to accelerate drug discovery. The company's platform combines hardware, software, and data to create a more efficient and effective drug discovery process. Recursion has a broad pipeline of drug candidates in development, and it has partnered with several leading pharmaceutical companies. The company is headquartered in Salt Lake City, Utah.

The Institute for Protein Design is a research institute at the University of Washington that uses computational design to create new proteins that solve modern challenges in medicine, technology, and sustainability. The institute's research focuses on developing new protein therapeutics, vaccines, drug delivery systems, biological devices, self-assembling nanomaterials, and bioactive peptides. The institute also has a strong commitment to responsible AI development and has developed a set of principles to guide its use of AI in research.

Allchemy is a resource-aware AI platform for drug discovery. It combines state-of-the-art computational synthesis with AI algorithms to predict molecular properties. Within minutes, Allchemy creates thousands of synthesizable lead candidates meeting user-defined profiles of drug-likeness, affinity towards specific proteins, toxicity, and a range of other physical-chemical measures. Allchemy encompasses the entire resource-to-drug design process and has been used in academic, corporate and classified environments worldwide to: Design synthesizable leads targeting specific proteins Evolve scaffolds similar to desired drugs Design “circular” drug syntheses from renewable materials Interface with and instruct automated synthesis platforms and optimize pilot-scale processes Operate “iterative synthesis” schemes Predict side reactions and create forensic “synthetic signatures” of hazardous/toxic molecules Design synthetic degradation and recovery cycles for various types of feedstocks and functional target molecules

Atomwise is an AI-powered drug discovery company that uses machine learning to identify new small molecule medicines. The company's platform combines the power of convolutional neural networks with massive chemical libraries to discover new drug candidates. Atomwise has a portfolio of wholly owned and co-developed pipeline assets, and is backed by prominent investors.

Wildlife Insights is an AI application that brings cutting-edge technology to wildlife conservation. It streamlines decision-making by providing machine learning models and tools to manage, analyze, and share camera trap data. Users can easily upload, identify, analyze, and discover wildlife through the platform, enabling better decisions to help wildlife thrive globally.

BioloGPT is an AI tool designed to answer biology-related questions with insights and graphs. It provides information on various topics such as maintaining a healthy gut microbiome, foods for a healthy immune system, effects of cannabis on the brain, risks of Covid-19 vaccines, and advancements in psoriasis treatment. The tool is updated daily and cites full papers to support its answers.

Bichos ID de Fucesa is an AI tool that allows users to explore and identify insects, arachnids, and other arthropods using artificial intelligence. Users can discover the most searched bugs, explore new discoveries made by the community, and view curated organisms. The platform aims to expand knowledge about the fascinating world of arthropods through AI-powered identification.

HoloEye.AI is a transformative AI biological intelligence company that leverages cutting-edge artificial intelligence technology to revolutionize the field of biological research. The platform offers advanced AI solutions for analyzing complex biological data, enabling researchers to gain deeper insights and accelerate scientific discoveries.

Lavo Life Sciences is an AI-accelerated crystal structure prediction application that aims to accelerate drug development processes. The platform provides solutions for de-risking pipelines, optimizing solid-state formulations, and avoiding late-stage surprises using AI technology. Lavo Life Sciences combines the expertise of chemists and engineers in AI and computational chemistry to offer innovative solutions for drug development teams.

Cradle is a protein engineering platform that uses machine learning to design improved protein sequences. It allows users to import assay data, generate new sequences, test them in the lab, and import the results to improve the model. Cradle can be used to optimize multiple properties of a protein simultaneously, and it has been used by leading biotech teams to accelerate new and ongoing projects.

C&EN, a publication of the American Chemical Society, provides the latest news and insights on the chemical industry, including research, technology, business, and policy. It covers a wide range of topics, including analytical chemistry, biological chemistry, business, careers, education, energy, environment, food, materials, people, pharmaceuticals, physical chemistry, policy, research integrity, safety, and synthesis.

CHAI AI Platform is an AI tool designed for quant traders to build and implement AI algorithms for trading. The platform combines chat functionality with AI capabilities to enhance the trading experience. Based in Palo Alto, CA, CHAI Research Corp. developed the platform to empower traders with advanced AI technology for better decision-making and performance in the financial markets.

SOMA is a Research Automation Platform that accelerates medical innovation by providing up to 100x speedup through process automation. The platform analyzes medical research articles, extracts important concepts, and identifies causal and associative relationships between them. It organizes this information into a specialized database forming a knowledge graph. Researchers can retrieve causal chains, access specific research articles, and perform tasks like concept analysis, drug repurposing, and target discovery. SOMA enhances literature review efficiency by finding relevant articles based on causal chains and keywords specified by the user. It empowers researchers to focus on their research by saving up to 95% of the time spent on pre-processing documents. The platform offers freemium access with extended functionality for 14 days and advanced features available through subscription.

Cambrian Copilot is an AI tool designed for researchers and engineers to easily stay up-to-date with the latest machine learning research. With over 240,000 ML papers available for search, the tool helps users understand complex details and automate literature reviews, simplifying the process of discovering and accessing cutting-edge research in the field of machine learning.

Mnemonic AI is an advanced Customer Intelligence AI tool that specializes in creating AI Personas and Digital Twin of the Customer. It helps organizations of all sizes better understand individuals by developing artificial intelligence solutions to tailor messages to their state of mind. The tool is fully automated, data-driven, and offers psychographics insights, integrations, and case studies to enhance customer centricity and marketing strategies.

functime is a time-series machine learning tool designed to perform forecasting at scale. It provides a comprehensive set of functions and resources to assist users in analyzing and evaluating time-series data. With features like scoring, ranking, and plotting functions, functime aims to simplify the process of forecasting and make it accessible to users of all levels of expertise. The tool also offers an API reference for developers looking to integrate time-series forecasting capabilities into their applications.

Kolank is an AI tool that provides a unified API for accessing a wide range of Language Model Models (LLMs) and providers. It offers features such as model comparison based on price, latency, output, context, and throughput, OpenAI compatible API integration, transparency in tracking API calls and token expenditure, cost reduction by paying for performance, load balancing with fallbacks, and easy integration with preferred LLMs using Python, Javascript, and Curl.

Promptmakr is a platform that facilitates the buying and selling of AI prompts. It serves as a marketplace where users can find and purchase prompts for various AI applications. The platform aims to streamline the process of acquiring prompts, making it easier for developers and AI enthusiasts to access high-quality content to enhance their projects.

StockGPT is an AI-powered financial research assistant that provides knowledge of earnings releases, financial reports, and fundamental information for S&P 500 and Nasdaq companies. It offers features like AI search, customizable filters, up-to-date data, industry research, and more to help users analyze companies and markets effectively.

Unlearn.ai is an AI-powered digital twins solution provider that optimizes clinical trials. Their TwinRCTs enable confident and quick clinical trials in various medical fields such as neuroscience, immunology, and metabolic diseases. By creating digital twins of patients, Unlearn.ai enhances the power and efficiency of clinical trials, attracting study participants and making confident decisions from early to late-stage studies.

Altera is an applied research lab focused on building digital human beings with fundamental human qualities. Led by Dr. Robert Yang, the team consists of computational neuroscientists, physics olympiads, and engineers from prestigious institutions. Their mission is to create digital beings that enhance human-to-human interactions, offering empathy, fun, friendship, and productivity at an unprecedented scale. Leveraging a state-of-the-art Composite Architecture inspired by the brain, Altera aims to develop agents with empathy, memory, and social norms. Starting with products in games, Altera plans to expand into multi-agent simulations and physical embodiment of digital intelligence, aspiring to become the most consequential technology company in the world.